NCT00331552View on ClinicalTrials.gov

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

February 29, 2012

Conditions
HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given orally

BIOLOGICAL

trastuzumab

Given IV

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00331552 - Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter